November 4, 2025 8:09am

It is sector earnings season and not to be merry; a cause and effect of weak trading sentiment, lack of breath, share pricing uneasiness and risk/reward depreciation

News: Sarepta Therapeutics (SRPT closed up +$0.44 with a pre-open of -$8.75 or -35.13%) stock crashed late Monday after 2 of its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys 53, failed their clinical studies. Both “HAD” won accelerated FDA approval based on early promise in clinical testing.

Earnings today: Ultragenyx Pharmaceuticals (RARE) and Supernus Therapeutics (SUPN).  

Pre-open Signals: 9 Negative Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Eventful week, the government remains shut down. Also, the Supreme Court is expected to hear oral arguments on legality of the Trump administration’s tariffs.

Monday night’s … RMi Closing Bell: Stripping the bark … https://www.regmedinvestors.com/articles/14179

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Tuesday: The pre-open Dow futures are DOWN -0.59% or (-282 points), the S&P futures are DOWN -0.98% or (-67 points) and the Nasdaq futures are DOWN -1.23% or (-322 points)

  • Stock futures fell dramatically, Tuesday 11/4
  • European markets were lower
  • Asia Pacific markets also traded lower

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed DOWN -226.19 points or -0.48%, the S&P closed UP +11.77 points or +0.17% while the Nasdaq closed UP +109,766 points or +0.46%
  • Friday: The Dow closed UP +40.75 points or +0.09%, the S&P closed UP +17.86 points or +0.26% while the Nasdaq closed UP +143.813 points or +0.61%
  • Last week: The S&P 500 was up 1.5%, the Dow +0.9% and the Nasdaq is up +3.2%
  • The previous week: the S&P 500 was up +2%, the Dow +2% and the Nasdaq added +2%.
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.
  • 2025 to date: the S&P is up +16%, the Nasdaq +22% and thew Dow +12%

 

Q4 – November, 1 negative session

  • October, 1 neutral, 10 positive and 12 negative closes
  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Info:

AxoGen (AXGN) closed up +$1.03 after Friday’s -$0.97 with a negative -$1.79 or -7.70% pre-open

Intellia Therapeutics (NTLA) closed up +$0.45 with a negative -$0.43 or -3.29% pre-open

Sarepta Therapeutics (SRPT) closed up +$0.44 after Friday’s +$1.11 with a negative -$8.45 or -35.13% pre-open

Vertex (VRTX) closed up +$0.43 after Friday’s +$5.9 with a negative -$17.98 or -4.22% pre-open

BioNTech (BNTX) closed up +$0.04 after Friday’s -$0.95 with a negative -$1.58 or -1.52% pre-open

uniQure NV (QURE) closed down -$33.40 after Friday’s -$0.62 with a negative -$3.19 or -9.30% pre-open

Alnylam Pharmaceuticals (ALNY) closed down -$22.12 after Friday’s +$6.98 with a negative -$7.39 or -1.70% pre-open

IQVIA Holdings (IQV) closed down -$2.58 after Friday’s -$0.46 with a negative -$2.14 or -1% pre-open

CRISPR Therapeutics (CRSP) closed down -$2.02 after Friday’s +$2.8 with a negative -$1.37 or -2.21% pre-open

 

The BOTTOM LINE: Feeling the drag…

The first trading day of November began on a downcast note while earnings reports keep getting released.

As the government shutdown continues becoming the longest in American history.

I got on my computer/laptop/ my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

Q3 Earnings this week: Regenxbio (RGNX), Moderna (MRNA) and Vericel (VCEL) on 11/6, followed by Cellectis SA CLLS) on 11/7 with Capricor Therapeutics (CAPR) on 11/10

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

  • As sector earnings meet, beat or miss expectations; whipsaw actions could ensue depreciations or the stock market heads south, back pedal -- fast.

The shutdown enters its 34th day and 6th today, with lawmakers still unable to agree on a funding bill … as Democrats block the 13th voting negotiation

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow review some of October:

  • 11/3 - Mondayclosed negative with 10 positive, 26 negative and 4 flats

Last week:

  • 10/31 – Friday closed positive with 28 positive, 11 negative and 1 flat
  • 10/30 – Thursday closed negative with 13 positive, 25 negative and 2 flats
  • 10/29 - Wednesday closed negative with 9 positive, 30 negative and 1 flat
  • 10/28 -Tuesday closed negative with 16 positive, 21 negative and 3 flats
  • 10/27- Monday closed negative with 18 positive, 22 negative and 0 flats

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.